You searched for Small Lymphocytic Lymphoma - Page 2 of 57

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL / SLL)

January 6, 2023

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with none of the more serious abnormal ventricular heart irregularities seen.

RESEARCH ON CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

December 6, 2022

WOULD YOU LIKE TO PARTICIPATE IN A DISCUSSION ABOUT CLL / SLL?
WE ARE RECRUITING PARTICIPANTS TO TAKE PART IN A ONE-ON-ONE INTERVIEW ABOUT CLL / SLL

Response to Vaccination in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

November 18, 2022

Dr. Susan Leclair has reviewed three abstracts from the 2021 American Society of Hematology Annual Meeting and Exposition, or ASH 2021, on chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients’ responses to vaccines, two on the COVID-19 vaccine, and one on the shingles vaccines.

Some Good News About Costs for Targeted Oral Anti-Cancer Drugs for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

October 21, 2022

Many chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients are insured under Medicare – either Original Medicare with a drug plan (Part A, B, and D “a la carte”) or a Medicare Advantage Plan (including Parts A, B, and D Prix fixe). Unfortunately, over the past several years, drug costs have risen significantly for targeted oral anti-cancer drugs.

ASCO 2022: A phase Ib/II Study of Lisaftoclax, a Novel BCL-2 inhibitor in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (R/R CLL / SLL)

October 19, 2022

It is much too early to predict how lisaftoclax will fit into the treatment paradigm for chronic lymphocytic leukemia/small lymphocytic lymphoma. Still, right now, it looks very similar to venetoclax, with the possible advantage of a faster ramp-up to the treatment dose

Dr. Michael Joyner on Convalescent Plasma for Treating COVID-19 in Immunocompromised Patients, including Those with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

October 12, 2022

In this interview, our own Dr. Brian Koffman spoke with Dr. Michael Joyner, an anesthesiologist at the Mayo Clinic in Rochester, MN. They discussed the use of convalescent plasma to treat COVID-19.

ASH 2021: MAJIC – A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

October 12, 2022

In summary, the results of MAJIC will help to inform the selection of time-limited doublet therapy approaches for patients with CLL / SLL and help define the duration of venetoclax in combination with either acalabrutinib or obinutuzumab.

ASH 2021: Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

September 22, 2022

Dr. Javier Pinilla Ibarz and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021).

ASH 2021: Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

September 13, 2022

Acalabrutinib plus high-frequency, low-dose subcutaneous rituximab is tolerable and effective. In addition, because it can be administered at home, it is more convenient and can decrease patient infection risk during pandemics. However, while it does control disease, it does not lead to undetectable measurable residual disease (uMRD).

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: Small Lymphocytic Lymphoma – Page 2